Crucell Inks European Distribution Deal With Sanquin For Cofact
This article was originally published in The Pink Sheet Daily
Executive Summary
Pact compliments April agreement with U.S. Bayer spin-off Talecris Biotherapeutics to distribute Prolastin.
You may also be interested in...
Crucell Gains Contract Manufacturing Company With SBL Acquisition
Acquisition, valued at $50.5 mil., is expected to complete on Nov. 23.
Novartis Considers Joining Swiss Vaccines Firm Berna With Chiron
The firm would have to outbid a roughly $450 mil. bid from Dutch biotech company Crucell.
Bayer To Retain Kogenate Line Following Plasma Unit Spin-Off
Company divests plasma products business to NPS BioTherapeutics under a $590 mil. agreement. Bayer will receive 10% equity in NPS, a new corporation formed by Cerebus Capital Management and Ampersand Ventures.